SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Warner Richard R. P.)
 

Sökning: WFRF:(Warner Richard R. P.) > (2021) > Time to Sustained I...

  • Dillon, Joseph S.Univ Iowa, Dept Internal Med Endocrinol & Metab, Iowa City, IA 52242 USA (författare)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl : Analyses of Phase III Studies in Carcinoid Syndrome

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2020-03-07
  • Springer Science and Business Media LLC,2021
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-454492
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-454492URI
  • https://doi.org/10.1007/s12029-020-00375-2DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BackgroundTelotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analogs. In TELESTAR and TELECAST phase III studies, patients with carcinoid syndrome received telotristat ethyl 250 or 500 mg 3 times per day (tid) or placebo tid in addition to somatostatin analogs. The aim of this prespecified analysis was to examine the time to reductions in bowel movements (BMs) in the TELESTAR and TELECAST studies using survival analysis methods.MethodsFirst occurrence of sustained response was defined as the time to the first day of 2 consecutive weeks with a mean BM frequency improvement of ≥ 30% from baseline during the 12-week double-blind treatment periods. Time to first ≥ 30% worsening in BM frequency was also measured. Treatments were compared with the log-rank test; Cox regression models provided point and confidence interval estimates of the hazard ratios for each trial.ResultsIn TELESTAR and TELECAST, majority of patients (69%) on telotristat ethyl experienced a sustained ≥ 30% improvement in BM frequency. The median time to sustained reduction of at least 30% in BM frequency was significantly faster (fewer days to onset) for telotristat ethyl compared with placebo in both TELESTAR (250 mg, HR = 2.3 [95% CI, 1.3–4.1, P = 0.004]; 500 mg, HR = 2.2 [95% CI, 1.2–3.9, P = 0.009]) and TELECAST (250 mg, HR = 3.9 [95% CI, 1.6–11.1, P = 0.003]; 500 mg, HR = 4.2 [95% CI, 1.7–11.7, P = 0.002]). In TELECAST, 42% of patients on placebo experienced sustained worsening in BM frequency compared with 20% on telotristat ethyl; no significant difference was observed in TELESTAR.ConclusionThe time of onset of sustained BM frequency improvement mean and range are important when considering use of telotristat ethyl in patients with carcinoid syndrome diarrhea. Telotristat ethyl may also reduce sustained worsening in BM frequency.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kulke, Matthew H.Boston Med Ctr, Div Med Oncol, Boston, MA USA (författare)
  • Hörsch, DieterZentralklin Bad Berka, Dept Gastroenterol Endocrinol, Ctr Neuroendocrine Tumors, Bad Berka, Germany (författare)
  • Anthony, Lowell B.Univ Kentucky, Div Med Oncol, Lexington, KY USA (författare)
  • Warner, Richard R. P.Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY 10029 USA (författare)
  • Bergsland, EmilyUniv Calif San Francisco, Dept Med, San Francisco, CA 94143 USA (författare)
  • Welin, StaffanUppsala universitet,Onkologisk endokrinologi(Swepub:uu)stafweli (författare)
  • O'Dorisio, Thomas M.Univ Iowa, Dept Internal Med Endocrinol & Metab, Iowa City, IA 52242 USA (författare)
  • Kunz, Pamela L.Stanford Univ, Dept Med, Div Oncol, Palo Alto, CA 94304 USA (författare)
  • McKee, ChadLexicon Pharmaceut Inc, The Woodlands, TX USA (författare)
  • Lapuerta, PabloLexicon Pharmaceut Inc, The Woodlands, TX USA (författare)
  • Banks, PhillipLexicon Pharmaceut Inc, The Woodlands, TX USA (författare)
  • Pavel, MarianneCharite, Dept Hepatol & Gastroenterol, Berlin, Germany; Friedrich Alexander Univ, Div Endocrinol, Dept Med 1, Erlangen, Germany (författare)
  • Univ Iowa, Dept Internal Med Endocrinol & Metab, Iowa City, IA 52242 USABoston Med Ctr, Div Med Oncol, Boston, MA USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Gastrointestinal Cancer: Springer Science and Business Media LLC52:1, s. 212-2211941-66281941-6636

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy